Olympus Corporation Consolidated Financial Results for the 3rd Quarter Fiscal 2023

Chikashi Takeda
Executive Officer and Chief Financial Officer
Nacho Abia
Executive Officer and Chief Operating Officer
Pierre Boisier
Chief Quality Officer

PLAY LIST

from the beginning

Consolidated Financial Results for the 3rd Quarter and Full-year Forecasts for Fiscal 2023

01. Consolidated Financial Results and Business Review for the 3Q of Fiscal 2023 (FY Ending March 31, 2023)

3Q of Fiscal 2023 (1) Consolidated Financial Results

3Q of Fiscal 2023 (2) Endoscopic Solutions Division (ESD)

3Q of Fiscal 2023 (3) Therapeutic Solutions Division (TSD)

Statement of Financial Position

Consolidated Cash Flows

02. Forecasts for Fiscal 2023

Fiscal 2023 Consolidated Forecasts

Fiscal 2023 Forecasts by Business Segment

FDA Warning Letters and Efforts to Strengthen QARA

Changes in Reporting Structure

3Q of Fiscal 2023 Factors that Affected Consolidated Operating Profit

3Q of Fiscal 2023 Discontinued Operation (Scientific Solutions Business)

3Q of Fiscal 2023 Results by Segment

Factors that Affected Consolidated Cash Flows

Key Product Catalysts: Endoscopic Solutions Division (As of Feb. 10, 2023)

Key Product Catalysts: Therapeutic Solutions Division (As of Feb. 10, 2023)

Expenditures, etc.

Foreign Exchange and Sensitivity

Q&A 1

Q&A 2

Q&A 3

Q&A 4

Q&A 5

Q&A 6

Back
Next

Download